Advertisement

Exfoliation Syndrome and Glaucoma

  • Anastasios G. P. Konstas
  • Gábor Holló
  • Robert Ritch
Chapter

Abstract

Exfoliative glaucoma (XFG) is the most common type of secondary open-angle glaucoma.1 Its worldwide prevalence makes it critical for ophthalmologists to be familiar with the full clinical spectrum of the disease.1–3 Exfoliation syndrome (XFS) and XFG were initially described in 1917 by the Finnish ophthalmologist John Lindberg. In 1924, it was determined that XFG develops from XFS. Both conditions currently affect 60-70 million people worldwide. Of these, 15-17 million people have increased intraocular pressure (IOP) and 5-6 million are estimated to suffer from XFG.3 Both XFS and XFG are characterized by the systemic synthesis and accumulation of an abnormal fibrillar material, called exfoliation material. Originally it was believed that the sole source of this abnormal material is the lens. The terms exfoliation material, XFS, XFG, and capsular glaucoma were introduced based on this early theory. True exfoliation of the lens capsule is a different and an exceedingly rare entity, which occurs as a consequence of thermal damage of the lens.

Keywords

Trabecular Meshwork Pigment Granule Selective Laser Trabeculoplasty POAG Patient Deep Sclerectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Supported in part by a Pythagoras grant (Dr. Konstas); a Hungarian National Health Grant (ETT 001/2009), (Dr. Holló); and a Horizon Award, Allergan, Inc., and Edith C. Blum Foundation, New York, NY (Dr. Ritch).

References

  1. 1.
    Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265–315.CrossRefPubMedGoogle Scholar
  2. 2.
    Ringvold A. Epidemiology of the pseudoexfoliation syndrome. A review. Acta Ophthalmol Scand. 1999;77:371–375.CrossRefPubMedGoogle Scholar
  3. 3.
    Ritch R, Schlotzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? Prog Retin Eye Res. 2003;22:253–275.CrossRefPubMedGoogle Scholar
  4. 4.
    Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397–1400.CrossRefPubMedGoogle Scholar
  5. 5.
    Fingert JH, Alward WA, Kwon YH, Wang K, Streb LM. LOXL1 mutations are associated with exfoliation syndrome in patients from the Midwestern United States. Am J Ophthalmol. 2007;144:974–975.CrossRefPubMedGoogle Scholar
  6. 6.
    Pasutto F, Krumbiegel M, Marin CY, et al. Associations of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1459–1463.CrossRefPubMedGoogle Scholar
  7. 7.
    Ozaki M, Lee KYC, Vithana FN, et al. Association of LOXL1 gene polymorphism with pseudoexfoliation in the Japanese. Invest Ophthalmol Vis Sci. 2008;49:3976–3980.CrossRefPubMedGoogle Scholar
  8. 8.
    Hayashi H, Gotoh N, Ueda Y, Nakanishi H, Yoshimura N. Lysyl oxidase-like 1 polymorphism and exfoliation syndrome in the Japanese population. Am J Ophthalmol. 2008;145:582–585.CrossRefPubMedGoogle Scholar
  9. 9.
    Schlötzer-Schrehardt U, Naumann GOH. Trabecular meshwork in pseudoexfoliation syndrome with and without open-angle glaucoma. Invest Ophthalmol Vis Sci. 1995;36:1750–1764.PubMedGoogle Scholar
  10. 10.
    Naumann GOH, Shclötzer-Schrehardt U, Kühle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Ophthalmology. 1998;105:951–968.CrossRefPubMedGoogle Scholar
  11. 11.
    Koliakos GG, Konstas AGP, Schrehardt-Schloetzer U, Bufidis T, Georgiadis N, Ringvold A. Ascorbic acid concentration is reduced in the aqueous humor of patients with exfoliation syndrome. Am J Ophthalmol. 2002;134:879–883.CrossRefPubMedGoogle Scholar
  12. 12.
    Visontai ZS, Horváth T, Kollai M, Holló G. Decreased cardiovagal regulation in exfoliation syndrome. J Glaucoma. 2008;17:133–138.CrossRefPubMedGoogle Scholar
  13. 13.
    Visontai Z, Merisch B, Kollai M, Holló G. Increase of carotid artery stiffness and decrease of baroreflex sensitivity in exfoliation syndrome and glaucoma. Br J Ophthalmol. 2006;90:563–567.CrossRefPubMedGoogle Scholar
  14. 14.
    Mitchell P, Wang JJ, Smith W. Association of pseudoexfolation syndrome with increased vascular risk. Am J Ophthalmol. 1997;124: 85–687.PubMedGoogle Scholar
  15. 15.
    Tarkkanen A, Kivelä T. Cumulative incidence of converting from clinically unilateral to bilateral exfoliation syndrome. J Glaucoma. 2004;13:181–184.CrossRefPubMedGoogle Scholar
  16. 16.
    Puska P. Unilateral exfoliation syndrome: conversion to bilateral exfoliation and to glaucoma. A prospective 10-year follow-up study. J Glaucoma. 2002;11:517–524.CrossRefPubMedGoogle Scholar
  17. 17.
    Konstas AGP, Matziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;28:111–117.Google Scholar
  18. 18.
    Konstas AGP, Holló G, Astakhov YS, et al. Presentation and long-term follow-up of exfoliation glaucoma in Greece, Spain, Russia and Hungary. Eur J Ophthalmol. 2006;16:60–66.PubMedGoogle Scholar
  19. 19.
    Thygesen J. Ocular clinical findings in exfoliation syndrome. In: Holló G, Konstas AGP, eds. Exfoliation Syndrome and Exfoliative Glaucoma. Savona, Italy: Dogma S.r.l; 2008:105–112.Google Scholar
  20. 20.
    Teus MA, de Benito-Llopis L. Update on cataract surgery in exfoliation syndrome. In: Holló G, Konstas AGP, eds. Exfoliation Syndrome and Exfoliative Glaucoma. Savona, Italy: Dogma S.r.l; 2007:127–132.Google Scholar
  21. 21.
    Vesti E, Kivel AT. Exfoliation syndrome and exfoliation glaucoma. Prog Retin Eye Res. 2000;19:268–345.CrossRefGoogle Scholar
  22. 22.
    Konstas AGP, Tsironi S, Kozobolis VP. Medical therapy of exfoliative glaucoma. In: Holló G, Konstas AGP, eds. Exfoliation Syndrome and Exfoliative Glaucoma. Savona, Italy: Dogma S.r.l; 2008:137–144.Google Scholar
  23. 23.
    Konstas AGP, Holló G, Akopov EL, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol. 2004;122:29–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Konstas AGP, Tsironi S, Ritch R. Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma. Compr Ophthalmol Update. 2006;7:131–141.PubMedGoogle Scholar
  25. 25.
    Takki KK, Klemetti A, Valle O. The IOP-lowering effect of timolol in simple and capsular glaucoma. A multicenter study in Finland. Graefes Arch Clin Exp Ophthalmol. 1982;218:83–87.CrossRefPubMedGoogle Scholar
  26. 26.
    Blika S, Saunte E. Timolol maleate in the treatment of glaucoma simplex and glaucoma capsulare. A three-year follow up study. Acta Ophthalmol (Copenh). 1982;60:967–976.CrossRefGoogle Scholar
  27. 27.
    Konstas AG, Matziris DA, Gate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:975–979.PubMedGoogle Scholar
  28. 28.
    Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology. 1997;104:137–142.PubMedGoogle Scholar
  29. 29.
    Konstas AGP, Maltezos A, Bufidis T, Hudgins AG, Stewart WC. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye. 2000;14:73–77.PubMedGoogle Scholar
  30. 30.
    Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73–80.PubMedGoogle Scholar
  31. 31.
    Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye. 2003;17:41–46.CrossRefPubMedGoogle Scholar
  32. 32.
    Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye. 2004;18:893–899.CrossRefPubMedGoogle Scholar
  33. 33.
    Konstas AGP, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653–657.CrossRefPubMedGoogle Scholar
  34. 34.
    Konstas AGP, Holló G, Irkec M, et al. Diurnal IOP control with bimatoprost vs latanoprost in exfoliative glaucoma: a crossover observer-masked 3-center study. Br J Ophthalmol. 2007;91:757–760.CrossRefPubMedGoogle Scholar
  35. 35.
    Stewart WC, Konstas AGP, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117–1122.CrossRefPubMedGoogle Scholar
  36. 36.
    Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N. Comparison of additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized open-label, multicenter study in Greece. J Glaucoma. 2001;10:316–324.CrossRefPubMedGoogle Scholar
  37. 37.
    Odberg T. Laser therapy of exfoliative glaucoma. In: Holló G, Konstas AGP, eds. Exfoliation Syndrome and Exfoliative Glaucoma. Savona, Italy: Dogma S.r.l; 2008:149–153.Google Scholar
  38. 38.
    Odberg T, Sandvik L. The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol Scand. 1999;77:176–181.CrossRefPubMedGoogle Scholar
  39. 39.
    Threlkeld A, Hertzmark E, Sturm RT, et al. Comparative study of the efficacy of argon laser trabeculoplasty for exfoliation and primary open-angle glaucoma. J Glaucoma. 1996;5:311–316.CrossRefPubMedGoogle Scholar
  40. 40.
    Higginbotham EJ, Richardson TM. Response of exfoliation glaucoma to laser trabeculoplasty. Br J Ophthalmol. 1986;70:837–839.CrossRefPubMedGoogle Scholar
  41. 41.
    Psilas P, Prevezas D, Petroutsos G, et al. Comparative study of argon laser trabeculoplasty in primary open-angle and pseudoexfoliation glaucoma. Ophthalmologica. 1989;198:57–63.CrossRefPubMedGoogle Scholar
  42. 42.
    Tuulonen A, Niva A-K, Alanko HI. A controlled five-year follow-up study of laser trabeculoplasty as primary therapy for open-angle glaucoma. Am J Ophthalmol. 1987;104:334–338.PubMedGoogle Scholar
  43. 43.
    Hodge WG, Damji KF, Rock W, Buhrmann R, Bowel AM, Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol. 2005;89:1157–1160.CrossRefPubMedGoogle Scholar
  44. 44.
    Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. Arch Ophthalmol. 2003;121:957–960.CrossRefPubMedGoogle Scholar
  45. 45.
    Kozobolis VP, Konstas AGP. Filtering surgery in exfoliative glaucoma. In: Holló G, Konstas AGP, eds. Exfoliation Syndrome and Exfoliative Glaucoma. Savona, Italy: Dogma S.r.l; 2008:157–161.Google Scholar
  46. 46.
    Tφrnqvist G, Drolsum L. Trabeculectomies. A long-term study. Acta Ophthalmol (Copenh). 1991;69:450–454.CrossRefGoogle Scholar
  47. 47.
    Popovic V, Sjostrand J. Course of exfoliation and simplex glaucoma after primary trabeculectomy. Br J Ophthalmol. 1999;83: 305–310.CrossRefPubMedGoogle Scholar
  48. 48.
    Konstas AGP, Jay JL, Marshall GE, Lee WR. Prevalence, diagnostic features and the response to trabeculectomy in exfoliation glaucoma. Ophthalmology. 1993;100:619–627.PubMedGoogle Scholar
  49. 49.
    Drolsum L. Deep sclerectomy in patients with capsular glaucoma. Acta Ophthalmol Scand. 2003;81:567–572.CrossRefPubMedGoogle Scholar
  50. 50.
    Kozobolis VP, Christodoulakis EV, Tzanakis N, Zacharopoulos I, Pallikaris IG. Primary deep sclerectomy versus primary deep sclerectomy with the use of mitomycin C in primary open-angle glaucoma. J Glaucoma. 2002;11:287–293.CrossRefPubMedGoogle Scholar
  51. 51.
    Shaarawy T, Nguyen C, Schnyder C, Mermoud A. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87:441–445.CrossRefPubMedGoogle Scholar
  52. 52.
    Wishart PK, Wishart MS, Porooshani H. Viscocanalostomy and deep sclerectomy for the surgical treatment of glaucoma: a longterm follow-up. Acta Ophthalmol Scand. 2003;81:343–348.CrossRefPubMedGoogle Scholar
  53. 53.
    Jacobi PC, Dietlein TS, Krieglstein GK. Comparative study of trabecular aspiration vs trabeculectomy in glaucoma triple procedure to treat pseudoexfoliation glaucoma. Arch Ophthalmol. 1999;117: 1311–1318.PubMedGoogle Scholar
  54. 54.
    Ritch R, Konstas AGP, Schlötzer-Schrehardt U: Exfoliation syndrome and exfoliative glaucoma. In Glaucoma: Medical diagnosis and therapy, Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, eds, Saunders 2009;1:339–348.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Anastasios G. P. Konstas
    • 1
  • Gábor Holló
    • 2
  • Robert Ritch
    • 3
    • 4
  1. 1.Head Glaucoma Unit, 1st University Department of Ophthalmology, Ahepa HospitalThessalonikiGreece
  2. 2.1st Department of OphthalmologySemmelweis University School of MedicineBudapestHungary
  3. 3.Department of OphthalmologyThe New York Eye and Ear InfirmaryNew YorkUSA
  4. 4.Department of OphthalmologyThe New York Medical CollegeValhallaUSA

Personalised recommendations